NASDAQ:STAA - STAAR Surgical Stock Price, Price Target & More

STAAR Surgical trades on the NASDAQ under the ticker symbol "STAA."

STAAR Surgical (NASDAQ:STAA) posted its quarterly earnings data on Wednesday, May, 2nd. The medical instruments supplier reported $0.04 EPS for the quarter, beating the consensus estimate of ($0.04) by $0.08. The medical instruments supplier had revenue of $27.09 million for the quarter, compared to analysts' expectations of $23 million. STAAR Surgical had a net margin of 0.66% and a return on equity of 6.80%. During the same period in the previous year, the firm posted ($0.05) EPS. View STAAR Surgical's Earnings History.

STAAR Surgical is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for STAAR Surgical.

4 Wall Street analysts have issued 1-year price targets for STAAR Surgical's shares. Their predictions range from $21.00 to $32.00. On average, they expect STAAR Surgical's stock price to reach $24.6667 in the next year. This suggests that the stock has a possible downside of 26.7%. View Analyst Ratings for STAAR Surgical.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for STAAR Surgical in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to STAAR Surgical include Envision Healthcare (EVHC), Aurora Cannabis (ACB), United Therapeutics (UTHR), STADA Arzneimittel (SAZ), FibroGen (FGEN), Loxo Oncology (LOXO), GALAPAGOS NV/S (GLPG), Agios Pharmaceuticals (AGIO), Masimo (MASI), Chemed (CHE), GN Store Nord A/S (GGNDF), Globus Medical (GMED), Foundation Medicine (FMI), Insulet (PODD) and Syneos Health (SYNH).

Media coverage about STAA stock has trended somewhat positive on Wednesday, according to Accern Sentiment. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. STAAR Surgical earned a media sentiment score of 0.11 on Accern's scale. They also assigned press coverage about the medical instruments supplier an impact score of 47.50 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

STAAR Surgical's stock is owned by many different of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (2.78%) and Columbia Partners L L C Investment Management (0.27%). Company insiders that own STAAR Surgical stock include Caren L Mason, Deborah J Andrews, Hans-Martin Blickensdoerfer, Keith Holliday and Samuel J Gesten. View Institutional Ownership Trends for STAAR Surgical.

STAA stock was purchased by a variety of institutional investors in the last quarter, including Columbia Partners L L C Investment Management and Baillie Gifford & Co.. View Insider Buying and Selling for STAAR Surgical.

Shares of STAA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of STAA stock can currently be purchased for approximately $33.65.

STAAR Surgical has a market capitalization of $1.36 billion and generates $90.61 million in revenue each year. The medical instruments supplier earns $-2,130,000.00 in net income (profit) each year or $0.01 on an earnings per share basis. STAAR Surgical employs 353 workers across the globe.

STAAR Surgical's mailing address is 1911 WALKER AVENUE, MONROVIA CA, 91016. The medical instruments supplier can be reached via phone at 626-303-7902 or via email at [email protected]